Akero Therapeutics, Inc. (NASDAQ:AKRO) COO Jonathan Young Sells 607 Shares

Akero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) COO Jonathan Young sold 607 shares of the firm's stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $44.88, for a total transaction of $27,242.16. Following the transaction, the chief operating officer now owns 200,540 shares of the company's stock, valued at approximately $9,000,235.20. The trade was a 0.30 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Jonathan Young also recently made the following trade(s):

• On Tuesday, March 4th, Jonathan Young sold 50,000 shares of Akero Therapeutics stock. The stock was sold at an average price of $44.86, for a total transaction of $2,243,000.00.
• On Monday, February 3rd, Jonathan Young sold 10,000 shares of Akero Therapeutics stock. The shares were sold at an average price of $53.81, for a total transaction of $538,100.00.
• On Thursday, January 2nd, Jonathan Young sold 10,000 shares of Akero Therapeutics stock. The stock was sold at an average price of $28.03, for a total value of $280,300.00.

Akero Therapeutics Stock Up 2.5 %

Shares of NASDAQ:AKRO traded up $1.10 during midday trading on Monday, hitting $45.25. 224,398 shares of the company's stock were exchanged, compared to its average volume of 810,503. The company has a debt-to-equity ratio of 0.05, a current ratio of 17.25 and a quick ratio of 17.25. Akero Therapeutics, Inc. has a 12 month low of $17.86 and a 12 month high of $58.40. The company has a market cap of $3.60 billion, a PE ratio of -12.01 and a beta of -0.19. The stock has a 50 day moving average price of $42.10 and a 200-day moving average price of $33.89.

Remove Ads

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last released its quarterly earnings results on Friday, February 28th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.98) by ($0.01). On average, sell-side analysts anticipate that Akero Therapeutics, Inc. will post -3.99 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the company. HC Wainwright raised their target price on Akero Therapeutics from $72.00 to $75.00 and gave the stock a "buy" rating in a research note on Monday, March 3rd. Citigroup boosted their target price on shares of Akero Therapeutics from $65.00 to $80.00 and gave the company a "buy" rating in a research report on Tuesday, January 28th. Bank of America raised shares of Akero Therapeutics from a "neutral" rating to a "buy" rating and increased their target price for the stock from $35.00 to $63.00 in a research note on Thursday, January 30th. UBS Group lifted their price target on shares of Akero Therapeutics from $42.00 to $109.00 and gave the company a "buy" rating in a research note on Friday, January 31st. Finally, Canaccord Genuity Group increased their price objective on shares of Akero Therapeutics from $56.00 to $73.00 and gave the stock a "buy" rating in a research report on Tuesday, January 28th. Nine equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $76.29.

Institutional Investors Weigh In On Akero Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Summit Investment Advisors Inc. grew its stake in shares of Akero Therapeutics by 6.8% in the 4th quarter. Summit Investment Advisors Inc. now owns 7,092 shares of the company's stock worth $197,000 after acquiring an additional 450 shares in the last quarter. Hsbc Holdings PLC grew its position in Akero Therapeutics by 8.5% in the 4th quarter. Hsbc Holdings PLC now owns 7,886 shares of the company's stock worth $220,000 after purchasing an additional 621 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Akero Therapeutics by 1.6% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 41,442 shares of the company's stock worth $1,153,000 after purchasing an additional 637 shares in the last quarter. Handelsbanken Fonder AB lifted its position in shares of Akero Therapeutics by 5.0% during the 4th quarter. Handelsbanken Fonder AB now owns 21,000 shares of the company's stock worth $584,000 after buying an additional 1,000 shares in the last quarter. Finally, Swiss National Bank boosted its stake in shares of Akero Therapeutics by 1.2% in the 4th quarter. Swiss National Bank now owns 95,600 shares of the company's stock worth $2,660,000 after buying an additional 1,100 shares during the last quarter.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.